The US Centers for Disease Control and Prevention has recommended a significant change in pneumococcal vaccination guidelines. Previously, the recommendation targeted adults aged 65 and older and children younger than five years. However, the CDC now suggests expanding this vaccination to include adults aged 50-64 years. This decision arises from a growing concern regarding the rising risk of pneumococcal disease in this age group.
Pneumococcal disease is caused by bacteria that can lead to severe illnesses, including pneumonia, meningitis, and bloodstream infections. The disease spreads through contact with respiratory secretions, such as saliva or mucus, making it easily transmissible.
The Advisory Committee on Immunization Practices voted 14 to 1 in favor of this recommendation, aiming to enhance public health by providing more individuals with the opportunity to protect themselves against pneumococcal infections at a critical age. This milestone in vaccination guidance is also expected to improve vaccination rates among susceptible populations.
The CDC emphasizes that individuals in the newly included age bracket are at an increased risk for contracting pneumococcal disease, which, if not treated promptly, can lead to severe complications.
Vaccines available in the US include options from Merck and Pfizer, which protect against multiple strains of the bacteria. Merck’s Pneumovax 23 and Vaxneuvance, as well as Pfizer’s Prevnar 20, are currently utilized to provide immunity against pneumococcal infections. Additionally, Merck’s new vaccine, Capvaxive, has been approved for adults aged 18 and over.
According to experts, pneumococcus can cause various infections, with pneumococcal meningitis and bacteremia being among the most severe. Symptoms can vary drastically depending on the infection’s location, with common signs including chest pain, cough, fever, and chills.
By lowering the vaccination age, healthcare professionals hope to decrease the incidence of this potentially debilitating disease and improve health outcomes for older adults and other vulnerable populations.
Source: Times Now
